Roles and Mechanisms of Deubiquitinases (DUBs) in Breast Cancer Progression and Targeted Drug Discovery
Abstract
:1. Introduction
2. DUBs in Breast Cancer Growth
2.1. DUBs of c-Myc
2.2. DUBs of KLF5
2.3. DUBs That Regulate H2B Monoubiquitination Levels
2.4. DUBs of Cell Cycle Regulatory Components
2.5. Other DUBs in Breast Cancer Growth
3. DUBs in Breast Cancer Metastasis
3.1. TGF-β Signaling Pathway
3.2. DUBs That Target EMT Regulators
3.3. Other DUBs Regulating Breast Cancer Metastasis
4. DUBs in Immunosuppression of Breast Cancer
5. DUBs in Chemoresistance and Chemosensitivity of Breast Cancer
5.1. Tamoxifen (SERM)
5.2. Enzalutamide (Antiandrogen)
5.3. Genotoxic Agents
5.4. PARPi
6. DUBs in Radioresistance and Radiosensitivity of Breast Cancer
7. Brief Summary
8. DUB Inhibitors for Breast Cancer Therapy
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Deng, L.; Meng, T.; Chen, L.; Wei, W.; Wang, P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct. Target. Ther. 2020, 5, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fraile, J.M.; Quesada, V.; Rodríguez, D.; Freije, J.M.P.; López-Otín, C. Deubiquitinases in cancer: New functions and therapeutic options. Oncogene 2012, 31, 2373–2388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harrigan, J.A.; Jacq, X.; Martin, N.M.; Jackson, S.P. Deubiquitylating enzymes and drug discovery: Emerging opportunities. Nat. Rev. Drug Discov. 2018, 17, 57–78. [Google Scholar] [CrossRef]
- Harbeck, N.; Penault-Llorca, F.; Cortes, J.; Gnant, M.; Houssami, N.; Poortmans, P.; Ruddy, K.; Tsang, J.; Cardoso, F. Breast cancer. Nat. Rev. Dis. Primers 2019, 5, 66. [Google Scholar] [CrossRef] [PubMed]
- Adhikary, S.; Eilers, M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 2005, 6, 635–645. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Wang, S.; Wang, M.; Qi, G.; Zhao, H. Ubiquitin-Specific Peptidase 5 is Involved in the Proliferation of Trophoblast Cells by Regulating Wnt/β-Catenin Signaling. Mol. Biotechnol. 2021, 63, 686–693. [Google Scholar] [CrossRef]
- Zhang, X.-Y.; Varthi, M.; Sykes, S.M.; Phillips, C.; Warzecha, C.; Zhu, W.; Wyce, A.; Thorne, A.W.; Berger, S.L.; McMahon, S.B. The Putative Cancer Stem Cell Marker USP22 Is a Subunit of the Human SAGA Complex Required for Activated Transcription and Cell-Cycle Progression. Mol. Cell 2008, 29, 102–111. [Google Scholar] [CrossRef] [Green Version]
- Kim, D.; Hong, A.; Park, H.I.; Shin, W.H.; Yoo, L.; Jeon, S.J.; Chung, K.C. Deubiquitinating enzyme USP22 positively regulates c-Myc stability and tumorigenic activity in mammalian and breast cancer cells. J. Cell. Physiol. 2017, 232, 3664–3676. [Google Scholar] [CrossRef]
- Sun, X.X.; He, X.; Yin, L.; Komada, M.; Sears, R.C.; Dai, M.S. The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc. Proc. Natl. Acad. Sci. USA 2015, 112, 3734–3739. [Google Scholar] [CrossRef] [Green Version]
- Farrugia, M.K.; Vanderbilt, D.B.; Salkeni, M.A.; Ruppert, J.M. Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses. Cancer Res. 2016, 76, 1677–1682. [Google Scholar] [CrossRef] [Green Version]
- Liu, R.; Zhou, Z.; Zhao, D.; Chen, C. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation. Mol. Endocrinol. 2011, 25, 1137–1144. [Google Scholar] [CrossRef] [Green Version]
- Tong, D.; Czerwenka, K.; Heinze, G.; Ryffel, M.; Schuster, E.; Witt, A.; Leodolter, S.; Zeillinger, R. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2006, 12, 2442–2448. [Google Scholar] [CrossRef] [Green Version]
- Wu, Y.; Qin, J.; Li, F.; Yang, C.; Li, Z.; Zhou, Z.; Zhang, H.; Li, Y.; Wang, X.; Liu, R.; et al. USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5. J. Biol. Chem. 2019, 294, 17837–17847. [Google Scholar] [CrossRef] [PubMed]
- Ge, F.; Chen, W.; Qin, J.; Zhou, Z.; Liu, R.; Liu, L.; Tan, J.; Zou, T.; Li, H.; Ren, G.; et al. Ataxin-3 like (ATXN3L), a member of the Josephin family of deubiquitinating enzymes, promotes breast cancer proliferation by deubiquitinating Krüppel-like factor 5 (KLF5). Oncotarget 2015, 6, 21369–21378. [Google Scholar] [CrossRef] [Green Version]
- Qin, J.; Zhou, Z.; Chen, W.; Wang, C.; Zhang, H.; Ge, G.; Shao, M.; You, D.; Fan, Z.; Xia, H.; et al. BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5. Nat. Commun. 2015, 6, 8471. [Google Scholar] [CrossRef]
- Yan, L.; Yu, M.C.; Gao, G.L.; Liang, H.W.; Zhou, X.Y.; Zhu, Z.T.; Zhang, C.Y.; Wang, Y.B.; Chen, X. MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1. J. Cell. Biochem. 2018, 119, 8773–8783. [Google Scholar] [CrossRef]
- Prenzel, T.; Begus-Nahrmann, Y.; Kramer, F.; Hennion, M.; Hsu, C.; Gorsler, T.; Hintermair, C.; Eick, D.; Kremmer, E.; Simons, M.; et al. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res. 2011, 71, 5739–5753. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Atanassov, B.S.; Mohan, R.D.; Lan, X.; Kuang, X.; Lu, Y.; Lin, K.; McIvor, E.; Li, W.; Zhang, Y.; Florens, L.; et al. ATXN7L3 and ENY2 Coordinate Activity of Multiple H2B Deubiquitinases Important for Cellular Proliferation and Tumor Growth. Mol. Cell 2016, 62, 558–571. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tarcic, O.; Granit, R.Z.; Pateras, I.S.; Masury, H.; Maly, B.; Zwang, Y.; Yarden, Y.; Gorgoulis, V.G.; Pikarsky, E.; Ben-Porath, I.; et al. RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer. Cell Death Differ. 2017, 24, 694–704. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ingham, M.; Schwartz, G.K. Cell-Cycle Therapeutics Come of Age. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2017, 35, 2949–2959. [Google Scholar] [CrossRef] [PubMed]
- Gennaro, V.J.; Stanek, T.J.; Peck, A.R.; Sun, Y.; Wang, F.; Qie, S.; Knudsen, K.E.; Rui, H.; Butt, T.; Diehl, J.A.; et al. Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proc. Natl. Acad. Sci. USA 2018, 115, E9298–E9307. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, S.; Zhong, X.; Wang, C.; Luo, H.; Lin, L.; Sun, H.; Sun, G.; Zeng, K.; Zou, R.; Liu, W.; et al. USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer. Cell Death Differ. 2020. [Google Scholar] [CrossRef]
- Liu, B.; Chen, J.; Zhang, S. Emerging role of ubiquitin-specific protease 14 in oncogenesis and development of tumor: Therapeutic implication. Life Sci. 2019, 239, 116875. [Google Scholar] [CrossRef] [PubMed]
- Zhu, L.; Yang, S.; He, S.; Qiang, F.; Cai, J.; Liu, R.; Gu, C.; Guo, Z.; Wang, C.; Zhang, W.; et al. Downregulation of ubiquitin-specific protease 14 (USP14) inhibits breast cancer cell proliferation and metastasis, but promotes apoptosis. J. Mol. Histol. 2016, 47, 69–80. [Google Scholar] [CrossRef]
- Liu, B.; Liu, Y.; Wang, Y.; Xie, C.; Gan, M.; Han, T.; Cao, J.; Wang, J. CyclinB1 deubiquitination by USP14 regulates cell cycle progression in breast cancer. Pathol. Res. Pract. 2019, 215, 152592. [Google Scholar] [CrossRef]
- Ding, K.; Li, W.; Zou, Z.; Zou, X.; Wang, C. CCNB1 is a prognostic biomarker for ER+ breast cancer. Med. Hypotheses 2014, 83, 359–364. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Kang, W.; You, Y.; Pang, J.; Ren, H.; Suo, Z.; Liu, H.; Zheng, Y. USP7: Novel Drug Target in Cancer Therapy. Front. Pharmacol. 2019, 10, 427. [Google Scholar] [CrossRef] [Green Version]
- Xia, X.; Liao, Y.; Huang, C.; Liu, Y.; He, J.; Shao, Z.; Jiang, L.; Dou, Q.P.; Liu, J.; Huang, H. Deubiquitination and stabilization of estrogen receptor α by ubiquitin-specific protease 7 promotes breast tumorigenesis. Cancer Lett. 2019, 465, 118–128. [Google Scholar] [CrossRef] [PubMed]
- Li, S.; Sun, A.; Liang, X.; Ma, L.; Shen, L.; Li, T.; Zheng, L.; Shang, W.; Zhao, W.; Jia, J. Histone demethylase PHF8 promotes progression and metastasis of gastric cancer. Am. J. Cancer Res. 2017, 7, 448–461. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, Q.; Pang, J.; Wang, L.A.; Huang, Z.; Xu, J.; Yang, X.; Xie, Q.; Huang, Y.; Tang, T.; Tong, D.; et al. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2. J. Pathol. 2021, 253, 106–118. [Google Scholar] [CrossRef]
- Wang, Q.; Ma, S.; Song, N.; Li, X.; Liu, L.; Yang, S.; Ding, X.; Shan, L.; Zhou, X.; Su, D.; et al. Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis. J. Clin. Investig. 2016, 126, 2205–2220. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Q.; Cao, C.; Gong, W.; Bao, K.; Wang, Q.; Wang, Y.; Bi, L.; Ma, S.; Zhao, J.; Liu, L.; et al. A feedforward circuit shaped by ECT2 and USP7 contributes to breast carcinogenesis. Theranostics 2020, 10, 10769–10790. [Google Scholar] [CrossRef] [PubMed]
- Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1, 555–567. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, L.; Qiang, J.; Yang, X.; Wang, D.; Rehman, A.U.; He, X.; Chen, W.; Sheng, D.; Zhou, L.; Jiang, Y.Z.; et al. IL1R2 Blockade Suppresses Breast Tumorigenesis and Progression by Impairing USP15-Dependent BMI1 Stability. Adv. Sci. 2020, 7, 1901728. [Google Scholar] [CrossRef] [Green Version]
- Srinivasan, M.; Bharali, D.J.; Sudha, T.; Khedr, M.; Guest, I.; Sell, S.; Glinsky, G.V.; Mousa, S.A. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation. Oncotarget 2017, 8, 38731–38742. [Google Scholar] [CrossRef] [Green Version]
- Du, T.; Li, H.; Fan, Y.; Yuan, L.; Guo, X.; Zhu, Q.; Yao, Y.; Li, X.; Liu, C.; Yu, X.; et al. The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis. Nat. Commun. 2019, 10, 2914. [Google Scholar] [CrossRef] [PubMed]
- Pu, Q.; Lv, Y.R.; Dong, K.; Geng, W.W.; Gao, H.D. Tumor suppressor OTUD3 induces growth inhibition and apoptosis by directly deubiquitinating and stabilizing p53 in invasive breast carcinoma cells. BMC Cancer 2020, 20, 583. [Google Scholar] [CrossRef] [PubMed]
- Yuan, L.; Lv, Y.; Li, H.; Gao, H.; Song, S.; Zhang, Y.; Xing, G.; Kong, X.; Wang, L.; Li, Y.; et al. Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis. Nat. Cell Biol. 2015, 17, 1169–1181. [Google Scholar] [CrossRef]
- Li, Y.; Jiang, D.; Zhang, Q.; Liu, X.; Cai, Z. Ubiquitin-specific protease 4 inhibits breast cancer cell growth through the upregulation of PDCD4. Int. J. Mol. Med. 2016, 38, 803–811. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Y.; Zhang, J.; Wu, L.; Liu, W.; Wei, G.; Gong, X.; Liu, Y.; Ma, Z.; Ma, F.; Thiery, J.P.; et al. Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth. Breast Cancer Res. BCR 2018, 20, 83. [Google Scholar] [CrossRef] [Green Version]
- Li, H.; Zheng, B. Overexpression of the Ubiquitin-Specific Peptidase 9 X-Linked (USP9X) Gene is Associated with Upregulation of Cyclin D1 (CCND1) and Downregulation of Cyclin-Dependent Inhibitor Kinase 1A (CDKN1A) in Breast Cancer Tissue and Cell Lines. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2019, 25, 4207–4216. [Google Scholar] [CrossRef]
- Lu, Q.; Lu, D.; Shao, Z.M.; Li, D.Q. Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells. Cancer Sci. 2019, 110, 1268–1278. [Google Scholar] [CrossRef] [Green Version]
- Wang, Z.; Nie, Z.; Chen, W.; Zhou, Z.; Kong, Q.; Seth, A.K.; Liu, R.; Chen, C. RNF115/BCA2 E3 ubiquitin ligase promotes breast cancer cell proliferation through targeting p21Waf1/Cip1 for ubiquitin-mediated degradation. Neoplasia 2013, 15, 1028–1035. [Google Scholar] [CrossRef] [Green Version]
- Klaus, A.; Birchmeier, W. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 2008, 8, 387–398. [Google Scholar] [CrossRef] [PubMed]
- Shang, Z.; Zhao, J.; Zhang, Q.; Cao, C.; Tian, S.; Zhang, K.; Liu, L.; Shi, L.; Yu, N.; Yang, S. USP9X-mediated deubiquitination of B-cell CLL/lymphoma 9 potentiates Wnt signaling and promotes breast carcinogenesis. J. Biol. Chem. 2019, 294, 9844–9857. [Google Scholar] [CrossRef]
- Li, X.; Song, N.; Liu, L.; Liu, X.; Ding, X.; Song, X.; Yang, S.; Shan, L.; Zhou, X.; Su, D.; et al. USP9X regulates centrosome duplication and promotes breast carcinogenesis. Nat. Commun. 2017, 8, 14866. [Google Scholar] [CrossRef]
- Li, L.; Liu, T.; Li, Y.; Wu, C.; Luo, K.; Yin, Y.; Chen, Y.; Nowsheen, S.; Wu, J.; Lou, Z.; et al. The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization. Oncogene 2018, 37, 2422–2431. [Google Scholar] [CrossRef] [PubMed]
- Toloczko, A.; Guo, F.; Yuen, H.F.; Wen, Q.; Wood, S.A.; Ong, Y.S.; Chan, P.Y.; Shaik, A.A.; Gunaratne, J.; Dunne, M.J.; et al. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway. Cancer Res. 2017, 77, 4921–4933. [Google Scholar] [CrossRef] [Green Version]
- Zhang, P.; Xiao, Z.; Wang, S.; Zhang, M.; Wei, Y.; Hang, Q.; Kim, J.; Yao, F.; Rodriguez-Aguayo, C.; Ton, B.N.; et al. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep. 2018, 23, 823–837. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, S.C. CYLD: A tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 2010, 17, 25–34. [Google Scholar] [CrossRef]
- Hayashi, M.; Jono, H.; Shinriki, S.; Nakamura, T.; Guo, J.; Sueta, A.; Tomiguchi, M.; Fujiwara, S.; Yamamoto-Ibusuki, M.; Murakami, K.; et al. Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res. Treat. 2014, 143, 447–457. [Google Scholar] [CrossRef] [PubMed]
- Orfanidou, T.; Xanthopoulos, K.; Dafou, D.; Pseftogas, A.; Hadweh, P.; Psyllaki, C.; Hatzivassiliou, E.; Mosialos, G. Down-regulation of the Tumor Suppressor CYLD Enhances the Transformed Phenotype of Human Breast Cancer Cells. Anticancer Res. 2017, 37, 3493–3503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brummelkamp, T.R.; Nijman, S.M.B.; Dirac, A.M.G.; Bernards, R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 2003, 424, 797–801. [Google Scholar] [CrossRef]
- Ren, Z.; Lv, M.; Yu, Q.; Bao, J.; Lou, K.; Li, X. MicroRNA-370-3p shuttled by breast cancer cell-derived extracellular vesicles induces fibroblast activation through the CYLD/Nf-κB axis to promote breast cancer progression. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2021, 35, e21383. [Google Scholar] [CrossRef]
- Song, H.; Li, D.; Wu, T.; Xie, D.; Hua, K.; Hu, J.; Deng, X.; Ji, C.; Deng, Y.; Fang, L. MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD. BMB Rep. 2018, 51, 602–607. [Google Scholar] [CrossRef] [Green Version]
- Matsuyama, Y.; Suzuki, M.; Arima, C.; Huang, Q.M.; Tomida, S.; Takeuchi, T.; Sugiyama, R.; Itoh, Y.; Yatabe, Y.; Goto, H.; et al. Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas. Mol. Carcinog. 2011, 50, 301–309. [Google Scholar] [CrossRef]
- Li, Y.; Huang, J.; Zeng, B.; Yang, D.; Sun, J.; Yin, X.; Lu, M.; Qiu, Z.; Peng, W.; Xiang, T.; et al. PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation. Cancer Lett. 2018, 430, 109–122. [Google Scholar] [CrossRef]
- Peng, L.; Hu, Y.; Chen, D.; Jiao, S.; Sun, S. Ubiquitin specific peptidase 21 regulates interleukin-8 expression, stem-cell like property of human renal cell carcinoma. Oncotarget 2016, 7, 42007–42016. [Google Scholar] [CrossRef] [Green Version]
- Arceci, A.; Bonacci, T.; Wang, X.; Stewart, K.; Damrauer, J.S.; Hoadley, K.A.; Emanuele, M.J. FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer. Cell Rep. 2019, 26, 3076–3086.e3076. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, X.; Liu, Z.; Zhang, L.; Yang, Z.; Chen, X.; Luo, J.; Zhou, Z.; Mei, X.; Yu, X.; Shao, Z.; et al. Targeting deubiquitinase USP28 for cancer therapy. Cell Death Dis. 2018, 9, 186. [Google Scholar] [CrossRef] [Green Version]
- Wu, Y.; Wang, Y.; Yang, X.H.; Kang, T.; Zhao, Y.; Wang, C.; Evers, B.M.; Zhou, B.P. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep. 2013, 5, 224–236. [Google Scholar] [CrossRef] [Green Version]
- Whyte, W.A.; Bilodeau, S.; Orlando, D.A.; Hoke, H.A.; Frampton, G.M.; Foster, C.T.; Cowley, S.M.; Young, R.A. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 2012, 482, 221–225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cao, C.; Vasilatos, S.N.; Bhargava, R.; Fine, J.L.; Oesterreich, S.; Davidson, N.E.; Huang, Y. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression. Oncogene 2017, 36, 133–145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Neuzillet, C.; Tijeras-Raballand, A.; Cohen, R.; Cros, J.; Faivre, S.; Raymond, E.; de Gramont, A. Targeting the TGFβ pathway for cancer therapy. Pharmacol. Ther. 2015, 147, 22–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, L.; Zhou, F.; Drabsch, Y.; Gao, R.; Snaar-Jagalska, B.E.; Mickanin, C.; Huang, H.; Sheppard, K.A.; Porter, J.A.; Lu, C.X.; et al. USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat. Cell Biol. 2012, 14, 717–726. [Google Scholar] [CrossRef] [PubMed]
- Eichhorn, P.J.A.; Rodón, L.; Gonzàlez-Juncà, A.; Dirac, A.; Gili, M.; Martínez-Sáez, E.; Aura, C.; Barba, I.; Peg, V.; Prat, A.; et al. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat. Med. 2012, 18, 429–435. [Google Scholar] [CrossRef]
- Liu, S.; González-Prieto, R.; Zhang, M.; Geurink, P.P.; Kooij, R.; Iyengar, P.V.; van Dinther, M.; Bos, E.; Zhang, X.; Le Dévédec, S.E.; et al. Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2020, 26, 1460–1473. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, L.; Zhou, F.; García de Vinuesa, A.; de Kruijf, E.M.; Mesker, W.E.; Hui, L.; Drabsch, Y.; Li, Y.; Bauer, A.; Rousseau, A.; et al. TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. Mol. Cell 2013, 51, 559–572. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Z.; Fan, Y.; Xie, F.; Zhou, H.; Jin, K.; Shao, L.; Shi, W.; Fang, P.; Yang, B.; van Dam, H.; et al. Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. Nat. Commun. 2017, 8, 2116. [Google Scholar] [CrossRef]
- Kavsak, P.; Rasmussen, R.K.; Causing, C.G.; Bonni, S.; Zhu, H.; Thomsen, G.H.; Wrana, J.L. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol. Cell 2000, 6, 1365–1375. [Google Scholar] [CrossRef]
- Wu, Y.; Yu, X.; Yi, X.; Wu, K.; Dwabe, S.; Atefi, M.; Elshimali, Y.; Kemp, K.T., 2nd; Bhat, K.; Haro, J.; et al. Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res. 2017, 77, 1383–1394. [Google Scholar] [CrossRef] [Green Version]
- Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196. [Google Scholar] [CrossRef] [Green Version]
- Mittal, V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu. Rev. Pathol. 2018, 13, 395–412. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Shi, J.; Chai, K.; Ying, X.; Zhou, B.P. The Role of Snail in EMT and Tumorigenesis. Curr. Cancer Drug Targets 2013, 13, 963–972. [Google Scholar] [CrossRef]
- Lambies, G.; Miceli, M.; Martínez-Guillamon, C.; Olivera-Salguero, R.; Peña, R.; Frías, C.P.; Calderón, I.; Atanassov, B.S.; Dent, S.Y.R.; Arribas, J.; et al. TGFβ-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1. Cancer Res. 2019, 79, 33–46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, W.; Shen, M.; Jiang, Y.Z.; Zhang, R.; Zheng, H.; Wei, Y.; Shao, Z.M.; Kang, Y. Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2. Genes Dev. 2020, 34, 1310–1315. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Li, J.; Ou, Y.; Yang, G.; Deng, K.; Wang, Q.; Wang, Z.; Wang, W.; Zhang, Q.; Wang, H.; et al. CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism. Signal Transduct. Target. Ther. 2020, 5, 25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, L.B.; Li, J.; Liao, W.T.; Feng, Y.; Yu, C.P.; Hu, L.J.; Kong, Q.L.; Xu, L.H.; Zhang, X.; Liu, W.L.; et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Investig. 2009, 119, 3626–3636. [Google Scholar] [CrossRef] [Green Version]
- He, J.; Lee, H.J.; Saha, S.; Ruan, D.; Guo, H.; Chan, C.H. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy. Cell Death Dis. 2019, 10, 285. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Yao, L.; Zhang, X.; Ji, H.; Wang, L.; Sun, S.; Pang, D. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J. Cancer Res. Clin. Oncol. 2011, 137, 1245–1253. [Google Scholar] [CrossRef]
- Jia, X.; Shi, L.; Wang, X.; Luo, L.; Ling, L.; Yin, J.; Song, Y.; Zhang, Z.; Qiu, N.; Liu, H.; et al. KLF5 regulated lncRNA RP1 promotes the growth and metastasis of breast cancer via repressing p27kip1 translation. Cell Death Dis. 2019, 10, 373. [Google Scholar] [CrossRef] [Green Version]
- Zou, H.; Chen, H.; Zhou, Z.; Wan, Y.; Liu, Z. ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4. Cancer Lett. 2019, 467, 19–28. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Z.; Zhou, H.; Ponzoni, L.; Luo, A.; Zhu, R.; He, M.; Huang, Y.; Guan, K.L.; Bahar, I.; Liu, Z.; et al. EIF3H Orchestrates Hippo Pathway-Mediated Oncogenesis via Catalytic Control of YAP Stability. Cancer Res. 2020, 80, 2550–2563. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, A.; Tang, M.; Zhang, L.; Wang, B.; Yang, Z.; Liu, Y.; Xu, G.; Wu, L.; Jing, T.; Xu, X.; et al. USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis. Oncogene 2019, 38, 2405–2419. [Google Scholar] [CrossRef] [PubMed]
- Goto, Y.; Zeng, L.; Yeom, C.J.; Zhu, Y.; Morinibu, A.; Shinomiya, K.; Kobayashi, M.; Hirota, K.; Itasaka, S.; Yoshimura, M.; et al. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat. Commun. 2015, 6, 6153. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; Wong, C.C.; Wei, H.; Gilkes, D.M.; Korangath, P.; Chaturvedi, P.; Schito, L.; Chen, J.; Krishnamachary, B.; Winnard, P.T., Jr.; et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012, 31, 1757–1770. [Google Scholar] [CrossRef]
- Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26, 677–704. [Google Scholar] [CrossRef] [Green Version]
- Xie, F.; Xu, M.; Lu, J.; Mao, L.; Wang, S. The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol. Cancer 2019, 18, 146. [Google Scholar] [CrossRef] [Green Version]
- Lim, S.O.; Li, C.W.; Xia, W.; Cha, J.H.; Chan, L.C.; Wu, Y.; Chang, S.S.; Lin, W.C.; Hsu, J.M.; Hsu, Y.H.; et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell 2016, 30, 925–939. [Google Scholar] [CrossRef] [Green Version]
- Zhang, M.; Wang, N.; Song, P.; Fu, Y.; Ren, Y.; Li, Z.; Wang, J. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 2020, 53, e12855. [Google Scholar] [CrossRef]
- Zhu, D.; Xu, R.; Huang, X.; Tang, Z.; Tian, Y.; Zhang, J.; Zheng, X. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 2020. [Google Scholar] [CrossRef]
- Ali, S.; Coombes, R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2002, 2, 101–112. [Google Scholar] [CrossRef] [PubMed]
- Niu, Z.; Li, X.; Feng, S.; Huang, Q.; Zhuang, T.; Yan, C.; Qian, H.; Ding, Y.; Zhu, J.; Xu, W. The deubiquitinating enzyme USP1 modulates ERα and modulates breast cancer progression. J. Cancer 2020, 11, 6992–7000. [Google Scholar] [CrossRef]
- Oosterkamp, H.M.; Hijmans, E.M.; Brummelkamp, T.R.; Canisius, S.; Wessels, L.F.; Zwart, W.; Bernards, R. USP9X downregulation renders breast cancer cells resistant to tamoxifen. Cancer Res. 2014, 74, 3810–3820. [Google Scholar] [CrossRef] [Green Version]
- Creighton, C.J.; Hilger, A.M.; Murthy, S.; Rae, J.M.; Chinnaiyan, A.M.; El-Ashry, D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res. 2006, 66, 3903–3911. [Google Scholar] [CrossRef] [Green Version]
- Chen, X.-S.; Wang, K.-S.; Guo, W.; Li, L.-Y.; Yu, P.; Sun, X.-Y.; Wang, H.-Y.; Guan, Y.-D.; Tao, Y.-G.; Ding, B.-N.; et al. UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer. Theranostics 2020, 10, 1833–1848. [Google Scholar] [CrossRef]
- Collins, L.C.; Cole, K.S.; Marotti, J.D.; Hu, R.; Schnitt, S.J.; Tamimi, R.M. Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses’ Health Study. Mod. Pathol. Off. J. U.S. Can. Acad. Pathol. Inc. 2011, 24, 924–931. [Google Scholar] [CrossRef] [Green Version]
- Kono, M.; Fujii, T.; Lim, B.; Karuturi, M.S.; Tripathy, D.; Ueno, N.T. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol. 2017, 3, 1266–1273. [Google Scholar] [CrossRef]
- Liao, Y.; Xia, X.; Liu, N.; Cai, J.; Guo, Z.; Li, Y.; Jiang, L.; Dou, Q.P.; Tang, D.; Huang, H.; et al. Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. Oncogene 2018, 37, 1896–1910. [Google Scholar] [CrossRef]
- Xia, X.; Huang, C.; Liao, Y.; Liu, Y.; He, J.; Guo, Z.; Jiang, L.; Wang, X.; Liu, J.; Huang, H. Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide. J. Exp. Clin. Cancer Res. CR 2019, 38, 220. [Google Scholar] [CrossRef] [Green Version]
- Shi, J.; Li, J.; Li, J.; Li, R.; Wu, X.; Gao, F.; Zou, L.; Mak, W.W.S.; Fu, C.; Zhang, J.; et al. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor. Phytomedicine Int. J. Phytother. Phytopharm. 2021, 81, 153408. [Google Scholar] [CrossRef]
- Melisko, M.E.; Assefa, M.; Hwang, J.; DeLuca, A.; Park, J.W.; Rugo, H.S. Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease. Breast Cancer Res. Treat. 2019, 177, 401–408. [Google Scholar] [CrossRef]
- Wang, H.; Guo, S.; Kim, S.J.; Shao, F.; Ho, J.W.K.; Wong, K.U.; Miao, Z.; Hao, D.; Zhao, M.; Xu, J.; et al. Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel. Theranostics 2021, 11, 2442–2459. [Google Scholar] [CrossRef]
- Heger, K.; Wickliffe, K.E.; Ndoja, A.; Zhang, J.; Murthy, A.; Dugger, D.L.; Maltzman, A.; de Sousa e Melo, F.; Hung, J.; Zeng, Y.; et al. OTULIN limits cell death and inflammation by deubiquitinating LUBAC. Nature 2018, 559, 120–124. [Google Scholar] [CrossRef]
- Wang, W.; Li, M.; Ponnusamy, S.; Chi, Y.; Xue, J.; Fahmy, B.; Fan, M.; Miranda-Carboni, G.A.; Narayanan, R.; Wu, J.; et al. ABL1-dependent OTULIN phosphorylation promotes genotoxic Wnt/β-catenin activation to enhance drug resistance in breast cancers. Nat. Commun. 2020, 11, 3965. [Google Scholar] [CrossRef] [PubMed]
- Fu, P.; Du, F.; Liu, Y.; Yao, M.; Zhang, S.; Zheng, X.; Zheng, S. WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells. Am. J. Transl. Res. 2017, 9, 1783–1791. [Google Scholar] [PubMed]
- Schwickart, M.; Huang, X.; Lill, J.R.; Liu, J.; Ferrando, R.; French, D.M.; Maecker, H.; O’Rourke, K.; Bazan, F.; Eastham-Anderson, J.; et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463, 103–107. [Google Scholar] [CrossRef] [PubMed]
- Wang, S.; Oh, D.Y.; Leventaki, V.; Drakos, E.; Zhang, R.; Sahin, A.A.; Resetkova, E.; Edgerton, M.E.; Wu, W.; Claret, F.X. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Lett. 2019, 465, 12–23. [Google Scholar] [CrossRef] [PubMed]
- Liu, G.; Yu, M.; Wu, B.; Guo, S.; Huang, X.; Zhou, F.; Claret, F.X.; Pan, Y. Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51. Cell. Signal. 2019, 53, 39–48. [Google Scholar] [CrossRef] [PubMed]
- Kurrey, N.K.; Jalgaonkar, S.P.; Joglekar, A.V.; Ghanate, A.D.; Chaskar, P.D.; Doiphode, R.Y.; Bapat, S.A. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27, 2059–2068. [Google Scholar] [CrossRef]
- Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917–921. [Google Scholar] [CrossRef]
- Peng, Y.; Liao, Q.; Tan, W.; Peng, C.; Hu, Z.; Chen, Y.; Li, Z.; Li, J.; Zhen, B.; Zhu, W.; et al. The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors. Nat. Commun. 2019, 10, 1224. [Google Scholar] [CrossRef] [Green Version]
- San Filippo, J.; Sung, P.; Klein, H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 2008, 77, 229–257. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Luo, K.; Li, L.; Li, Y.; Wu, C.; Yin, Y.; Chen, Y.; Deng, M.; Nowsheen, S.; Yuan, J.; Lou, Z. A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination. Genes Dev. 2016, 30, 2581–2595. [Google Scholar] [CrossRef] [PubMed]
- Poulsen, M.; Lukas, C.; Lukas, J.; Bekker-Jensen, S.; Mailand, N. Human RNF169 is a negative regulator of the ubiquitin-dependent response to DNA double-strand breaks. J. Cell Biol. 2012, 197, 189–199. [Google Scholar] [CrossRef] [Green Version]
- An, L.; Jiang, Y.; Ng, H.H.; Man, E.P.; Chen, J.; Khoo, U.S.; Gong, Q.; Huen, M.S. Dual-utility NLS drives RNF169-dependent DNA damage responses. Proc. Natl. Acad. Sci. USA 2017, 114, E2872–E2881. [Google Scholar] [CrossRef] [Green Version]
- Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444, 756–760. [Google Scholar] [CrossRef]
- Zhang, P.; Wei, Y.; Wang, L.; Debeb, B.G.; Yuan, Y.; Zhang, J.; Yuan, J.; Wang, M.; Chen, D.; Sun, Y.; et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat. Cell Biol. 2014, 16, 864–875. [Google Scholar] [CrossRef]
- Wang, B.; Zheng, J.; Li, R.; Tian, Y.; Lin, J.; Liang, Y.; Sun, Q.; Xu, A.; Zheng, R.; Liu, M.; et al. Long noncoding RNA LINC02582 acts downstream of miR-200c to promote radioresistance through CHK1 in breast cancer cells. Cell Death Dis. 2019, 10, 764. [Google Scholar] [CrossRef]
- King, H.O.; Brend, T.; Payne, H.L.; Wright, A.; Ward, T.A.; Patel, K.; Egnuni, T.; Stead, L.F.; Patel, A.; Wurdak, H.; et al. RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells. Stem Cell Rep. 2017, 8, 125–139. [Google Scholar] [CrossRef] [Green Version]
- Yang, S.; Liu, L.; Cao, C.; Song, N.; Wang, Y.; Ma, S.; Zhang, Q.; Yu, N.; Ding, X.; Yang, F.; et al. USP52 acts as a deubiquitinase and promotes histone chaperone ASF1A stabilization. Nat. Commun. 2018, 9, 1285. [Google Scholar] [CrossRef]
- Nakashima, R.; Goto, Y.; Koyasu, S.; Kobayashi, M.; Morinibu, A.; Yoshimura, M.; Hiraoka, M.; Hammond, E.M.; Harada, H. UCHL1-HIF-1 axis-mediated antioxidant property of cancer cells as a therapeutic target for radiosensitization. Sci. Rep. 2017, 7, 6879. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xiao, H.; Claret, F.X.; Shen, Q. The novel Jab1 inhibitor CSN5i-3 suppresses cell proliferation and induces apoptosis in human breast cancer cells. Neoplasma 2019, 66, 481–486. [Google Scholar] [CrossRef]
- Song, Z.; Tu, X.; Zhou, Q.; Huang, J.; Chen, Y.; Liu, J.; Lee, S.; Kim, W.; Nowsheen, S.; Luo, K.; et al. A novel UCHL(3) inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair. Cell Death Dis. 2019, 10, 398. [Google Scholar] [CrossRef] [Green Version]
- Lee, B.H.; Lee, M.J.; Park, S.; Oh, D.C.; Elsasser, S.; Chen, P.C.; Gartner, C.; Dimova, N.; Hanna, J.; Gygi, S.P.; et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010, 467, 179–184. [Google Scholar] [CrossRef] [Green Version]
- Farshi, P.; Deshmukh, R.R.; Nwankwo, J.O.; Arkwright, R.T.; Cvek, B.; Liu, J.; Dou, Q.P. Deubiquitinases (DUBs) and DUB inhibitors: A patent review. Expert Opin. Pat. 2015, 25, 1191–1208. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- D’Arcy, P.; Brnjic, S.; Olofsson, M.H.; Fryknäs, M.; Lindsten, K.; De Cesare, M.; Perego, P.; Sadeghi, B.; Hassan, M.; Larsson, R.; et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med. 2011, 17, 1636–1640. [Google Scholar] [CrossRef]
- Vogel, R.I.; Coughlin, K.; Scotti, A.; Iizuka, Y.; Anchoori, R.; Roden, R.B.; Marastoni, M.; Bazzaro, M. Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells. Oncotarget 2015, 6, 4159–4170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Foley, M.; Tait, B.; Cullen, M.J.W. Proteostasis Regulators. WO Patent WO2012154967A1, 15 November 2012. [Google Scholar]
- Hedstrom, L.K.; Long, M.J.C.; Baggio, R.F.; Lawson, A.P. Inhibitors of Deubiquitinating Proteases. U.S. Patent US20160090351A1, 31 March 2016. [Google Scholar]
- Goetz, M.P.; Boughey, J.C.; Wang, L.; Kalari, K.R.; Weinshilboum, R.M.; Suman, V.J. Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer. U.S. Patent US10,220,016, 5 March 2019. [Google Scholar]
- Chen, J.; Dexheimer, T.S.; Ai, Y.; Liang, Q.; Villamil, M.A.; Inglese, J.; Maloney, D.J.; Jadhav, A.; Simeonov, A.; Zhuang, Z. Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem. Biol. 2011, 18, 1390–1400. [Google Scholar] [CrossRef] [Green Version]
- Maloney, D.J.; Rosenthal, A.S.; Jadhav, A.; Dexheimer, T.S.; Simeonov, A.; Zhuang, Z.; Liang, Q.; Luci, D.K. Inhibitors of the USP1/UAF1 Deubiquitinase Complex and Uses Thereof. WO Patent WO2014105952A2, 3 July 2014. [Google Scholar]
- Zudaire, E.; Aparicio, M.; Cuttitta, F. Antiangiogenic Small Molecules and Methods of Use. U.S. Patent US9,186,365, 17 November 2015. [Google Scholar]
- Kotha, R.R.; Luthria, D.L. Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects. Molecules 2019, 24, 2930. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schlierf, A.; Altmann, E.; Quancard, J.; Jefferson, A.B.; Assenberg, R.; Renatus, M.; Jones, M.; Hassiepen, U.; Schaefer, M.; Kiffe, M.; et al. Targeted inhibition of the COP9 signalosome for treatment of cancer. Nat. Commun. 2016, 7, 13166. [Google Scholar] [CrossRef] [PubMed]
- Poradosu, E.; Sportelli, P. Perifosine and Capecitabine as a Combined Treatment for Cancer. U.S. Patent US8,383,607, 26 February 2013. [Google Scholar]
- Chen, S.; Liu, Y.; Zhou, H. Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors. Int. J. Mol. Sci. 2021, 22, 4546. [Google Scholar] [CrossRef]
Family | DUB | Substrates | Effects | References |
---|---|---|---|---|
USP | USP7 | ERα, PHF8, ECT2 | promote tumor growth | [28,31,32] |
RNF169 | promote chemoresistance | [116] | ||
PHF8, CHK1 | promote radioresistance | [31,118] | ||
USP14 | CyclinB1 | promote tumor growth | [24,25] | |
AR | promote chemoresistance | [99,100] | ||
USP22 | H2B, c-Myc, CCND1, ERα | promote tumor growth | [8,18,21,22] | |
c-Myc | promote tumor metastasis | [8,80] | ||
ERα | promote chemoresistance | [22] | ||
USP36 | c-Myc | promote tumor growth | [9] | |
USP15 | BMI1 | promote tumor growth | [34] | |
BMI1, TβRI | promote tumor metastasis | [34,66] | ||
BARD1 | promote chemoresistance | [112] | ||
USP44 | H2B | promote or suppress tumor growth | [19] | |
USP3 | KLF5 | promote tumor growth | [13] | |
USP4 | PDCD4, HDAC2 | promote or suppress tumor growth | [39,40] | |
TβRI | promote tumor metastasis | [65] | ||
USP9X | RNF115, BCL9, CEP131, YAP1, LATS | promote or suppress tumor growth | [41,42,45,46,47,48] | |
RNF115, BCL9, SMAD4 | promote tumor metastasis | [42,45,71] | ||
ERα cofactors, MCL1 | promote chemoresistance | [94,107] | ||
USP21 | FOXM1 | promote tumor growth | [59] | |
USP28 | LSD1 | promote tumor growth | [61] | |
CYLD | NEMO and upstream regulatory factors of IKK | suppress tumor growth | [51,52] | |
USP27X | Snail1 | promote tumor metastasis | [75] | |
Snail1 | promote chemoresistance | [75] | ||
USP20 | SNAI2 | promote tumor metastasis | [76] | |
USP51 | ZEB1 | promote tumor metastasis | [77] | |
USP2 | BMI1 | promote tumor metastasis | [79] | |
USP1 | KPNA2 | promote tumor metastasis | [84] | |
ERα | promote chemoresistance | [93] | ||
USP52 | ASF1A | promote radioresistance | [121] | |
OTU | OTUD3 | p53, PTEN | suppress tumor growth | [37,38] |
ZRANB1 | EZH2 | promote tumor growth | [49] | |
OTUD1 | SMAD7 | suppress tumor metastasis | [69] | |
OTUB1 | PD-L1 | promote immune escape | [91] | |
OTULIN | β-catenin | promote chemoresistance | [105] | |
JAMM | PSMD2 | p21, p27 | promote tumor growth | [57] |
EIF3H | YAP | promote tumor metastasis | [83] | |
Jab1/CSN5 | PD-L1 | promote immune escape | [89] | |
Rad51 | promote chemoresistance | [108,109] | ||
MJD | ATXN3L | KLF5 | promote tumor growth | [14] |
ATXN3 | KLF4 | promote tumor metastasis | [82] | |
UCH | BAP1 | KLF5 | promote tumor growth | [15] |
KLF5 | promote tumor metastasis | [15] | ||
UCHL1 | TβRI, HIF-1 | promote tumor metastasis | [67,85] | |
UCHL3 | Rad51 | promote chemoresistance | [114] | |
Rad51 | promote radioresistance | [114] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Li, S.; Zhang, H.; Wei, X. Roles and Mechanisms of Deubiquitinases (DUBs) in Breast Cancer Progression and Targeted Drug Discovery. Life 2021, 11, 965. https://doi.org/10.3390/life11090965
Li S, Zhang H, Wei X. Roles and Mechanisms of Deubiquitinases (DUBs) in Breast Cancer Progression and Targeted Drug Discovery. Life. 2021; 11(9):965. https://doi.org/10.3390/life11090965
Chicago/Turabian StyleLi, Sixuan, Hongquan Zhang, and Xiaofan Wei. 2021. "Roles and Mechanisms of Deubiquitinases (DUBs) in Breast Cancer Progression and Targeted Drug Discovery" Life 11, no. 9: 965. https://doi.org/10.3390/life11090965